Innate Pharma downgraded by H.C. Wainwright
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
H.C. Wainwright downgraded Innate Pharma from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2025 | Buy → Neutral | H.C. Wainwright | |
| 9/18/2025 | Outperform → Market Perform | Leerink Partners | |
| 7/28/2025 | $8.00 | Buy | BTIG Research |
| 9/17/2021 | $7.00 → $9.00 | Outperform | SVB Leerink |
| 9/3/2021 | $7.00 | Mkt Perform → Outperform | SVB Leerink |
| 9/3/2021 | Market Perform → Outperform | SVB Leerink | |
| 9/2/2021 | Market Perform → Outperform | SVB Leerink |
6-K - Innate Pharma SA (0001598599) (Filer)
6-K - Innate Pharma SA (0001598599) (Filer)
6-K - Innate Pharma SA (0001598599) (Filer)
H.C. Wainwright downgraded Innate Pharma from Buy to Neutral
Leerink Partners downgraded Innate Pharma from Outperform to Market Perform
BTIG Research initiated coverage of Innate Pharma with a rating of Buy and set a new price target of $8.00
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financial reports are released before market opens CET. All corporate information, such as the Company's financial statements and corporate presentations, is available on the Investors section on the Company website. About Innate Pharma In
Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of November 27, 2025: Total number of shares outstanding: 92,196,523 ordinary shares 6,334 Preferred Shares 2016 7,581 Preferred Shares 2017 Total number of theoretical voting rights (1): Total number of exercisable voting rights (2): 92,962,943 92,944,368 (1) The total number of theoretical voting
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its executive team will participate in one-on-one meetings and present on Monday, November 17, 2025. Jefferies Global Healthcare Conference Date: November 17, 2025 Time: 2:30–2:55 PM GMT / 9:30–9:55 AM ET / 3:30–3:55 PM CET Location: London, UK A live webcast will be available on the Events page in the Investors section of Innate Pharma website. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its exper
Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from
Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe
Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Ch
Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 Cash position of € 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced its business update and financial results for the first nine mon
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Stéphanie Cornen, Vice President, Investor Relation, Communication and Commercial Strategy Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The liv
IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA. Monalizumab: AstraZeneca Phase 3 PACIFIC-9 enrollment is completed and high level read-out is expected in H2 2026. Strategic focus: Innate Pharma plans to prioritize its investment in what it
SC 13D/A - Innate Pharma SA (0001598599) (Subject)
SC 13D/A - Innate Pharma SA (0001598599) (Subject)
SC 13D - Innate Pharma SA (0001598599) (Subject)